Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa
Liver International · 2024-04 · 44 (4) · 1061-1070
DOI: 10.1111/liv.15852 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Liver International, online erschienen am 02.02.2024. Verfasst von Zobair M Younossi und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH Council, Center for Outcomes Research in Liver Disease, Washington, DC, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Beatty Liver and Obesity Research Program, The Global NASH Council, The King Faisal Specialist Hospital and Research Centre.
Abstract (Originalsprache)
Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed the prevalence of NAFLD/MASLD in the general population and among patients with T2D in the Middle East and North Africa (MENA) region.
Methods
We searched PubMed and Embase for English‐language articles published between 1990 and 2023 according to PRISMA. Each country's NAFLD/MASLD prevalence in the general population and in T2D patients was predicted by using a multivariable meta regression model. Input data were extracted from our systematic review, GBD and NCD Risk Factor Collaboration. Confidence intervals were constructed by using prediction intervals with the delta method.
Results
Meta‐analytic pooling estimated the prevalence of NAFLD/MASLD as 39.43% in the general population and 68.71% among T2D patients. NAFLD/MASLD prevalence has increased from 35.42% (2008–2016) to 46.20% (2017–2020). Using GBD‐2019 dataset, it was predicted that there are 141.51 million cases of NAFLD/MASLD in the MENA region. The highest number of NAFLD/MASLD cases were expected in Egypt (25.71 million), followed by Türkiye (23.33 million) and Iran (19.85 million). Estimated NAFLD prevalence exceeded 40% in 10 of 21 countries with the top countries being Kuwait (45.37%), Egypt (45.0%), Qatar (44.4%), and Jordan (43.3%). Furthermore, it was predicted that there are 24.96 million cases of NAFLD/MASLD with T2D in the MENA region.
Conclusions
In the MENA region, prevalence of NAFLD/MASLD is very high and growing, necessitating an urgent need for regional public policy to deal with this growing burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Global NASH Council, Center for Outcomes Research in Liver Disease, Washington, DC, USA.
- Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
- Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey.
- Department of Endemic Medicine, Faculty in Medicine, Helwan University, Cairo, Egypt.
- Liver Disease Research Center, Department of Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
- Division of Gastroenterology & Hepatology, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Zobair M Younossi, Pegah Golabi, James Paik, Soroor Owrangi, Yusuf Yilmaz, Mohamed El-Kassas, Khalid Alswat, Saleh A Alqahtani
Förderung
- Beatty Liver and Obesity Research Program
- The Global NASH Council
- The King Faisal Specialist Hospital and Research Centre
Zitieren
APA
Younossi, Z. M., Golabi, P., Paik, J., Owrangi, S., Yilmaz, Y., El-Kassas, M., Alswat, K., & Alqahtani, S. A. (2024). Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa. Liver International, 44(4), 1061-1070. https://doi.org/10.1111/liv.15852
Vancouver
Younossi ZM, Golabi P, Paik J, Owrangi S, Yilmaz Y, El-Kassas M, et al. Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa. Liver International. 2024;44(4):1061-1070. doi:10.1111/liv.15852
BibTeX
@article{Younossi2024,
author = {Younossi, Zobair M and Golabi, Pegah and Paik, James and Owrangi, Soroor and Yilmaz, Yusuf and El-Kassas, Mohamed and Alswat, Khalid and Alqahtani, Saleh A},
title = {Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa},
journal = {Liver International},
year = {2024},
volume = {44},
number = {4},
pages = {1061--1070},
doi = {10.1111/liv.15852}
}
EUVIMED